Results 1 to 10 of about 467,609 (357)

A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1) [PDF]

open access: yesHaematologica, 2008
Acute myeloid leukemia with mutated NPM1 gene and aberrant cytoplasmic expression of nucleophosmin (NPMc+ acute myeloid leukemia) shows distinctive biological and clinical features.
Arcangelo Liso   +22 more
doaj   +5 more sources

Long-term experience in treatment of acute promyelocytic leukemia in Mexican children in a tertiary care hospital

open access: yesFrontiers in Oncology, 2023
IntroductionAcute promyelocytic leukemia (APL) is a rare myeloid leukemia subtype affecting adult and pediatric populations. APL constitutes 15-20% of all childhood AML in Latin America, compared to 7% in the non-Latino population.
Marco Antonio Murillo-Maldonado   +7 more
doaj   +1 more source

Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers

open access: yesHaematologica, 2021
Cancer treatment is constantly evolving from a one-size-fits-all towards bespoke approaches for each patient. In certain solid cancers, including breast and lung, tumor genome profiling has been incorporated into therapeutic decision-making. For chronic
Vaidehi Krishnan   +4 more
doaj   +1 more source

Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients

open access: yesHemaSphere, 2021
Tyrosine kinase inhibitors have dramatically changed the outcome of chronic myeloid leukemia (CML), and nowadays, one of the main treatment goals is the achievement of deep molecular responses (DMRs), which can eventually lead to therapy discontinuation ...
Natalia Estrada   +12 more
doaj   +1 more source

Socioeconomic cost of AML in Sweden—A population‐based study using multiple nation‐wide registers

open access: yeseJHaem, 2021
Acute myeloid leukemia (AML) is associated with a high economic and clinical burden. Recently novel therapies have been added to standard treatment regimens. Here, we evaluated the economic impact of AML up until the introduction of these novel therapies.
Emma Hernlund   +6 more
doaj   +1 more source

Acute myeloid leukemia: update in diagnosis and treatment in Brazil [PDF]

open access: yesEinstein (São Paulo), 2011
Objective: To identify how the Brazilian hematology centers treated and diagnosed cases of acute myeloid leukemia in 2009. Methods: An epidemiological observational multicenter study of 11 listed Brazilian centers that treat acute myeloid leukemia and ...
Ricardo Helman   +12 more
doaj   +3 more sources

CREB is a critical regulator of normal hematopoiesis and leukemogenesis [PDF]

open access: yes, 2008
The cAMP-responsive element binding protein (CREB) is a 43-kDa nuclear transcription factor that regulates cell growth, memory, and glucose homeostasis. We showed previously that CREB is amplified in myeloid leukemia blasts and expressed at higher levels
Akashi   +55 more
core   +3 more sources

Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options [PDF]

open access: yes, 2018
The onset of global epigenetic changes in chromatin that drive tumor proliferation and heterogeneity is a hallmark of many forms cancer. Identifying the epigenetic mechanisms that govern these changes and developing therapeutic approaches to modulate ...
Koschmieder, Steffen, Vetrie, David
core   +1 more source

Acute Myeloid Leukemia

open access: yesHematology, 2004
AbstractAdvances in our understanding of the pathophysiology of acute myeloid leukemia (AML) have not yet led to major improvements in disease-free and overall survival of adults with this disease. Only about one-third of those between ages 18–60 who are diagnosed with AML can be cured; disease-free survival is rare and current therapy devastating in ...
Richard M, Stone   +2 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy